ZIOPHARM Oncology, Inc. (ZIOP)
Price:
0.87 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
NEWS
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday
fool.com
2022-01-19 17:35:01The clinical-stage biotech saw a slight bounce-back from its lows of last week.
ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-11-23 06:58:07ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.
ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-08 19:45:04ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
globenewswire.com
2021-11-01 16:30:00HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results.
Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch
pennystocks.com
2021-10-06 07:48:52Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?
ZIOP Stock: Why It Decreased Today
pulse2.com
2021-09-28 05:53:04The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) fell over 8% during pre-market today. This is why it happened.
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
globenewswire.com
2021-09-27 16:05:00• Over 50% reduction in personnel
Here's Why Ziopharm Oncology Stock Is Up 18% This Week
fool.com
2021-09-10 09:00:24Recent insider stock purchases were more than a little encouraging.
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
zacks.com
2021-09-08 10:14:57Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
ZIOP Stock: Over 45% Increase Explanation
pulse2.com
2021-09-07 12:12:07The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) increased by over 45% during intraday trading. This is why it happened.
Why Shares of Ziopharm Oncology Jumped on Wednesday
fool.com
2021-09-01 16:36:28The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.
Ziopharm Oncology to Participate in September Investor Conferences
globenewswire.com
2021-09-01 16:05:00BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences:
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
globenewswire.com
2021-08-30 08:30:00Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles
ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-08-09 21:48:10ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
globenewswire.com
2021-07-26 16:30:00BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.
Ziopharm Oncology to Participate in Upcoming Conferences
globenewswire.com
2021-05-24 16:05:00BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:
No data to display
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday
fool.com
2022-01-19 17:35:01The clinical-stage biotech saw a slight bounce-back from its lows of last week.
ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?
zacks.com
2021-11-23 06:58:07ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.
ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-08 19:45:04ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
globenewswire.com
2021-11-01 16:30:00HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results.
Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch
pennystocks.com
2021-10-06 07:48:52Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?
ZIOP Stock: Why It Decreased Today
pulse2.com
2021-09-28 05:53:04The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) fell over 8% during pre-market today. This is why it happened.
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
globenewswire.com
2021-09-27 16:05:00• Over 50% reduction in personnel
Here's Why Ziopharm Oncology Stock Is Up 18% This Week
fool.com
2021-09-10 09:00:24Recent insider stock purchases were more than a little encouraging.
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
zacks.com
2021-09-08 10:14:57Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
ZIOP Stock: Over 45% Increase Explanation
pulse2.com
2021-09-07 12:12:07The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) increased by over 45% during intraday trading. This is why it happened.
Why Shares of Ziopharm Oncology Jumped on Wednesday
fool.com
2021-09-01 16:36:28The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.
Ziopharm Oncology to Participate in September Investor Conferences
globenewswire.com
2021-09-01 16:05:00BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences:
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
globenewswire.com
2021-08-30 08:30:00Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles
ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-08-09 21:48:10ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
globenewswire.com
2021-07-26 16:30:00BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.
Ziopharm Oncology to Participate in Upcoming Conferences
globenewswire.com
2021-05-24 16:05:00BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences: